RxVantage

RxVantage

Interaction management system for healthcare providers and medical companies.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor investor

€0.0

round
investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
*

N/A

Late VC
Total Funding000k
Notes (0)
More about RxVantage
Made with AI
Edit

RxVantage has developed a healthcare management platform that simplifies communication between medical practitioners and life science representatives. The platform allows medical offices to schedule and manage meetings with representatives, giving them access to the latest medical information and resources.

The company's cloud-based software is designed to improve the efficiency of communication between medical practices and life science companies. It provides a streamlined process for healthcare providers to connect with pharmaceutical company representatives and other medical experts. This helps to ensure that medical practices have access to the information they need to provide the best possible care to their patients.

RxVantage's business model is centered on its online platform, which acts as a central hub for communication and collaboration between healthcare providers and life science companies. The company generates revenue by charging a fee for access to its platform and services. RxVantage is based in Providence, Rhode Island, and has a team of over 150 employees. The company has reported annual revenues of $21 million.

Keywords: healthcare management, life science, medical communication, physician access, pharma marketing, B2B healthcare, medical education, practice management, rep scheduling, health-tech

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by RxVantage

Edit
OnPoint Oncology
ACQUISITION by RxVantage Nov 2020